WAVE LIFE SCIENCES LTD (WVE) Stock Price, Quote, News and Overview
NASDAQ:WVE - Nasdaq - SG9999014716 - Common Stock - Currency: USD
WVE Quote, Performance and Key Statistics
5.95
-0.14 (-2.3%)
The current stock price of WVE is 5.95 USD. In the past month the price decreased by -11.59%. In the past year, price decreased by -4.34%.
WVE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.87 | 676.41B | ||
| JNJ | JOHNSON & JOHNSON | 15.22 | 367.98B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.92 | 299.26B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.57 | 222.69B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16 | 218.30B | ||
| MRK | MERCK & CO. INC. | 9.96 | 194.81B | ||
| PFE | PFIZER INC | 7.26 | 132.58B | ||
| SNY | SANOFI-ADR | 11.79 | 126.50B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.38 | 95.34B | ||
| GSK | GSK PLC-SPON ADR | 8.73 | 78.45B | ||
| ZTS | ZOETIS INC | 27.01 | 72.38B | ||
| HLN | HALEON PLC-ADR | 22.73 | 50.17B |
Related stock screener links
About WVE
Company Profile
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company employs 287 full-time employees The company went IPO on 2015-11-11. The firm is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. The company is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
Company Info
WAVE LIFE SCIENCES LTD
7 Straits View, #12-00, Marina One East Tower
Singapore 018936 SG
CEO: Paul B. Bolno
Employees: 288
Phone: 6562363388
WAVE LIFE SCIENCES LTD / WVE FAQ
What is the stock price of WAVE LIFE SCIENCES LTD today?
The current stock price of WVE is 5.95 USD. The price decreased by -2.3% in the last trading session.
What is the ticker symbol for WAVE LIFE SCIENCES LTD stock?
The exchange symbol of WAVE LIFE SCIENCES LTD is WVE and it is listed on the Nasdaq exchange.
On which exchange is WVE stock listed?
WVE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for WAVE LIFE SCIENCES LTD stock?
17 analysts have analysed WVE and the average price target is 21.93 USD. This implies a price increase of 268.57% is expected in the next year compared to the current price of 5.95. Check the WAVE LIFE SCIENCES LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is WAVE LIFE SCIENCES LTD worth?
WAVE LIFE SCIENCES LTD (WVE) has a market capitalization of 917.07M USD. This makes WVE a Small Cap stock.
How many employees does WAVE LIFE SCIENCES LTD have?
WAVE LIFE SCIENCES LTD (WVE) currently has 288 employees.
What are the support and resistance levels for WAVE LIFE SCIENCES LTD (WVE) stock?
WAVE LIFE SCIENCES LTD (WVE) has a support level at 5.82 and a resistance level at 6.15. Check the full technical report for a detailed analysis of WVE support and resistance levels.
Is WAVE LIFE SCIENCES LTD (WVE) expected to grow?
The Revenue of WAVE LIFE SCIENCES LTD (WVE) is expected to grow by 24.36% in the next year. Check the estimates tab for more information on the WVE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy WAVE LIFE SCIENCES LTD (WVE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of WVE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of WVE, evaluating the profitability, health, valuation and growth aspects
- WAVE LIFE SCIENCES LTD (WVE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- WAVE LIFE SCIENCES LTD (WVE) Sales and EPS estimates to see what analysts future expectations are.
- WAVE LIFE SCIENCES LTD (WVE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- WAVE LIFE SCIENCES LTD (WVE) Insider and Institutional Ownership to learn about the owners and their transactions.
- WAVE LIFE SCIENCES LTD (WVE) Stock Chart to make your own analysis
- WAVE LIFE SCIENCES LTD (WVE) Latest news and press-releases to stay up to date.
Does WAVE LIFE SCIENCES LTD (WVE) stock pay dividends?
WVE does not pay a dividend.
When does WAVE LIFE SCIENCES LTD (WVE) report earnings?
WAVE LIFE SCIENCES LTD (WVE) will report earnings on 2025-08-06, before the market open.
What is the Price/Earnings (PE) ratio of WAVE LIFE SCIENCES LTD (WVE)?
WAVE LIFE SCIENCES LTD (WVE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.84).
What is the Short Interest ratio of WAVE LIFE SCIENCES LTD (WVE) stock?
The outstanding short interest for WAVE LIFE SCIENCES LTD (WVE) is 10.28% of its float. Check the ownership tab for more information on the WVE short interest.
WVE Technical Analysis
WVE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to WVE. WVE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
WVE Financial Highlights
Over the last trailing twelve months WVE reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS decreased by -61.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.96% | ||
| ROE | -62.52% | ||
| Debt/Equity | 0 |
WVE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to WVE. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -25.42% and a revenue growth 24.36% for WVE